Arax Advisory Partners
HCAT icon

Arax Advisory Partners’s Health Catalyst HCAT Stock Holding History

Arax Advisory Partners’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9K Buy
9,997
+9,870
+7,772% +$14.2K ﹤0.01% 3965
2026
Q1 		$161 Buy
127
+90
+243% +$169 ﹤0.01% 3567
2025
Q4 		$88 Sell
37
-594
-94% -$1.62K ﹤0.01% 3850
2025
Q3 		$1.8K Buy
+631
New +$2.16K ﹤0.01% 3136
2025
Q2 		– Sell
-223
Closed -$1.01K – 3119
2025
Q1 		$1.01K Sell
223
-440
-66% -$2.33K ﹤0.01% 2299
2024
Q4 		$4.69K Buy
663
+164
+33% +$1.31K ﹤0.01% 1762
2024
Q3 		$4.06K Hold
499
– – ﹤0.01% 1803
2024
Q2 		$3.19K Buy
+499
New +$3.2K ﹤0.01% 1798

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $239M AUM
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's HCAT Position: Q2 2026 in Review

Arax Advisory Partners increased its Health Catalyst (HCAT) stake by 7,772% in Q2 2026, buying an estimated $14.2K and bringing the position to 9,997 shares worth $19.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3965.

Arax Advisory Partners first reported a position in HCAT in Q2 2024 and has held it in 8 quarters since. 126 funds tracked by Wall St. Rank hold HCAT as of Q2 2026.

  • Arax Advisory Partners held 9,997 shares of Health Catalyst worth $19.9K as of Q2 2026.
  • Arax Advisory Partners bought 9,870 Health Catalyst shares in Q2 2026, an estimated $14.2K.
  • Health Catalyst made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3965 holding.
  • Arax Advisory Partners first reported a position in Health Catalyst in Q2 2024 and has held it in 8 quarters since.
  • 126 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.